An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma

In an open-label, phase II study, we evaluated entospletinib monotherapy for patients with relapsed or refractory diffuse large B-cell lymphoma. Entospletinib had limited activity in these patients. Seventy-four percent of the patients experienced a grade ≥ 3 adverse event. Treatment was interrupted...

Descripción completa

Detalles Bibliográficos
Autores principales: Burke, John M., Shustov, Andrei, Essell, James, Patel-Donnelly, Dipti, Yang, Jay, Chen, Robert, Ye, Wei, Shi, Wen, Assouline, Sarit, Sharman, Jeff
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857170/
https://www.ncbi.nlm.nih.gov/pubmed/29934062
http://dx.doi.org/10.1016/j.clml.2018.05.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857170/
https://www.ncbi.nlm.nih.gov/pubmed/29934062
http://dx.doi.org/10.1016/j.clml.2018.05.022

Ejemplares similares